- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00025324
Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors
Clinical Correlative Studies In Primary Central Nervous System Germ Cell Tumors: The Third International CNS Germ Cell Tumor Study Group Protocol
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells.
PURPOSE: Phase II trial to study the effectiveness of chemotherapy, surgery, radiation therapy, and bone marrow or peripheral stem cell transplantation in treating patients who have primary CNS germ cell tumors.
Study Overview
Status
Conditions
Intervention / Treatment
- Drug: carboplatin
- Drug: cyclophosphamide
- Radiation: radiation therapy
- Drug: etoposide
- Drug: thiotepa
- Procedure: conventional surgery
- Procedure: peripheral blood stem cell transplantation
- Biological: filgrastim
- Procedure: autologous bone marrow transplantation
- Procedure: bone marrow ablation with stem cell support
Detailed Description
OBJECTIVES:
- Determine the two-year event-free survival of patients with primary CNS germ cell tumors treated with carboplatin, etoposide, cyclophosphamide, and filgrastim (G-CSF) with or without radiotherapy and/or high-dose chemotherapy with autologous bone marrow or peripheral blood stem cell transplantation.
- Determine the prognostic significance of slow-responding tumor marker normalization in patients treated with this regimen.
- Determine the prognostic significance of syncytiotrophoblastic giant cell component and cerebrospinal fluid beta-human chorionic gonadotropin elevation in patients treated with this regimen.
- Assess the early and late endocrinologic, neuropsychometric, and quality of life sequelae in patients treated with this regimen.
OUTLINE: This is a multicenter study. Patients are stratified according to risk status (low vs intermediate or high).
Regimen A (Low-risk patients)
- Chemotherapy: Patients receive carboplatin IV over 4 hours and etoposide IV over 2 hours on days 1-2 and filgrastim (G-CSF) subcutaneously (SC) once daily beginning on day 3 and continuing until blood counts recover (course 1). Patients also receive cyclophosphamide IV over 1 hour and etoposide IV over 2 hours on days 22 and 23 and G-CSF SC once daily beginning on day 24 and continuing until blood counts recover (course 2).
- Patients with complete response (CR) to initial chemotherapy receive 2 additional courses of chemotherapy as above and then proceed to observational phase. Patients with partial response (PR) to initial chemotherapy receive 2 additional courses of chemotherapy as above.
- Patients with CR after additional chemotherapy receive another 2 additional courses of chemotherapy as above and then proceed to observational phase. Patients with PR after additional chemotherapy undergo biopsy and/or resection of residual tumor.
- Patients with evidence of malignant germ cell tumor (GCT) on resection undergo radiotherapy. Patients with no evidence of malignant GCT on resection but with scar, fibrosis, or mature teratoma receive 2 additional courses of chemotherapy as above and then proceed to observational phase. Patients with no evidence of malignant GCT on resection but with immature teratoma receive carboplatin IV over 4 hours, cyclophosphamide IV over 1 hour, and etoposide IV over 2 hours on days 1-2 and 22-23. Patients who underwent complete resection of residual tumor proceed to observational phase. Patients who underwent a biopsy only or an incomplete resection of residual tumor undergo radiotherapy.
Regimen B (Intermediate and high-risk patients)
- Patients receive carboplatin IV over 4 hours, cyclophosphamide IV over 1 hour, and etoposide IV over 2 hours on days 0-1. Patients also receive G-CSF SC once daily beginning on day 2 and continuing until blood counts recover. Treatment repeats every 21 days for a total of 2 courses. Patients undergo bone marrow or peripheral blood stem cell harvest prior to second course of chemotherapy.
- Patients with rapid CR to 2 initial courses of chemotherapy receive an additional 2 courses of chemotherapy as above and then proceed to observational phase. Patients with a PR or slow response to 2 initial courses of chemotherapy receive 2 additional courses of chemotherapy as above. Patients with a CR to courses 3 and 4 receive 2 more courses of chemotherapy and then proceed to observational phase. Patients with a PR to courses 3 and 4 undergo a biopsy and/or resection of residual tumor.
- Patients with no evidence of malignant GCT on resection but with scar, fibrosis, or mature teratoma receive carboplatin IV over 4 hours and etoposide IV over 2 hours on days 1 and 2 and cyclophosphamide IV over 1 hour and etoposide IV over 2 hours on days 22 and 23 and proceed to observational phase. Patients with teratoma on resection receive additional treatment as in regimen A. Patients with evidence of pure germinoma on resection undergo radiotherapy.
- Patients with evidence of other malignant GCT on resection undergo high-dose chemotherapy (HDCx) with bone marrow or peripheral blood stem cell support (PBSCS) comprising thiotepa IV over 3 hours and etoposide IV over 1 hour on days -8 through -6; carboplatin IV over 4 hours on days -5 through -3; reinfusion of autologous bone marrow or peripheral blood stem cells on day 0; and G-CSF SC or IV every 12 hours beginning on day 1 and continuing until blood counts recover. Patients then undergo radiotherapy.
Quality of life is assessed before bone marrow or PBSCS and then every 2 years thereafter.
Patients are followed at day 42, at 3 months, then every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 80 patients (40 per stratum) will be accrued for this study within 4 years.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Western Australia
-
Perth, Western Australia, Australia, 6001
- Princess Margaret Hospital for Children
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Centre - Calgary
-
-
-
-
California
-
Los Angeles, California, United States, 90027-0700
- Children's Hospital Los Angeles
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Children's Hospital of The King's Daughters
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
- Histologically confirmed newly diagnosed primary CNS germ cell tumor OR
- Serum or cerebrospinal fluid (CSF) elevation of alpha-fetoprotein (AFP) or beta-human chorionic gonadotropin (beta-HCG) greater than 50 ng/mL
Low-risk disease:
- Histologically proven pure germinoma
- Localized, nonmetastatic disease
- Normal CSF
- Normal serum tumor markers
Intermediate-risk disease:
- Histologically proven germinoma
- Beta-HCG-positive syncytiotrophoblastic giant cell component AND/OR
- CSF elevation of beta-HCG to less than 50 ng/mL
High-risk disease:
- Histologically proven choriocarcinoma, endodermal sinus tumor, or embryonal carcinoma
- Elevated serum and/or CSF AFP OR
- Elevated serum beta-HCG OR
- Elevated CSF beta-HCG greater than 50 ng/mL OR
- Disseminated disease by MRI and/or CSF cytology
PATIENT CHARACTERISTICS:
Age:
- Any age
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Bilirubin less than 2.0 mg/dL
- Indirect hyperbilirubinemia due to Gilbert's syndrome is allowed
- AST and ALT less than 5 times upper limit of normal
Renal:
- Creatinine clearance greater than 60 mL/min
Cardiovascular:
- Cardiac function normal by echocardiogram
- No myocardial infarction or ischemia in patients over 30 years
- Fractional shortening greater than 30%
Other:
- No unacceptable morbidity of organ systems outside the CNS
- Not pregnant
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy
Endocrine therapy:
- No concurrent corticosteroids administered solely for antiemesis during study chemotherapy
Radiotherapy:
- No prior cranial radiotherapy
Surgery:
- Not specified
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Jonathan L. Finlay, MB, ChB, Children's Hospital Los Angeles
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Germ Cell and Embryonal
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Cyclophosphamide
- Carboplatin
- Etoposide
- Thiotepa
Other Study ID Numbers
- CDR0000068950
- CHLA-NYU-0007H
- NCI-G01-2019
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain and Central Nervous System Tumors
-
Children's Hospital Los AngelesUnknownBrain and Central Nervous System TumorsUnited States, Canada, Australia, Switzerland, New Zealand
-
Emory UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Abramson Cancer Center of the University of PennsylvaniaNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)CompletedVNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain TumorsBrain and Central Nervous System TumorsUnited States
-
St. Jude Children's Research HospitalCompletedBrain Tumors | Central Nervous System TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumors | Central Nervous System TumorsUnited States, Australia, Canada
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
National Cancer Institute (NCI)CompletedBrain and Central Nervous System Tumors
Clinical Trials on carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Samyang Biopharmaceuticals CorporationCompleted
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedBrain and Central Nervous System TumorsUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
AkesoRecruitingAdvanced Squamous Non Small Cell Lung CancerChina
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Eli Lilly and CompanyCompletedLung NeoplasmsUnited States